Spelman, T. Et Al. 2023. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry. MULTIPLE SCLEROSIS JOURNAL , vol.29, no.2 , 221-235.

Spelman, T., ÖZAKBAŞ, S., Alroughani, R., TERZİ, M., Hodgkinson, S., Laureys, G., ... Kalincik, T.(2023). Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry. MULTIPLE SCLEROSIS JOURNAL , vol.29, no.2, 221-235.

Spelman, Tim Et Al. "Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry," MULTIPLE SCLEROSIS JOURNAL , vol.29, no.2, 221-235, 2023

Spelman, Tim Et Al. "Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry." MULTIPLE SCLEROSIS JOURNAL , vol.29, no.2, pp.221-235, 2023

Spelman, T. Et Al. (2023) . "Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry." MULTIPLE SCLEROSIS JOURNAL , vol.29, no.2, pp.221-235.

@article{article, author={Tim Spelman Et Al. }, title={Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry}, journal={MULTIPLE SCLEROSIS JOURNAL}, year=2023, pages={221-235} }